GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Cash Flow from Financing

Exelixis (Exelixis) Cash Flow from Financing

: $-546 Mil (TTM As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Exelixis paid $0 Mil more to buy back shares than it received from issuing new shares. It received $0 Mil from issuing more debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0 Mil from paying cash dividends to shareholders. It received $0 Mil on other financial activities. In all, Exelixis spent $0 Mil on financial activities for the three months ended in Dec. 2023.


Exelixis Cash Flow from Financing Historical Data

The historical data trend for Exelixis's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.55 -25.13 -14.80 0.59 -546.05

Exelixis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.00 4.59 -124.79 -219.67 -206.17

Exelixis Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Exelixis's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Exelixis's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-546 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exelixis  (NAS:EXEL) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Exelixis's issuance of stock for the three months ended in Dec. 2023 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Exelixis's repurchase of stock for the three months ended in Dec. 2023 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Exelixis's net issuance of debt for the three months ended in Dec. 2023 was $0 Mil. Exelixis received $0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Exelixis's net issuance of preferred for the three months ended in Dec. 2023 was $0 Mil. Exelixis paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Exelixis's cash flow for dividends for the three months ended in Dec. 2023 was $0 Mil. Exelixis received $0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Exelixis's other financing for the three months ended in Dec. 2023 was $0 Mil. Exelixis received $0 Mil on other financial activities.


Exelixis Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Exelixis's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083